Levcromakalim
Levcromakalim is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 5 | 5 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 3 | 3 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | — | 2 | 2 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 2 | 2 |
| Cerebrovascular circulation | D002560 | — | — | — | — | 1 | 1 | ||
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | — | — | — | 1 | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | — | 1 | 1 |
| Post-traumatic headache | D051298 | G44.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LEVCROMAKALIM |
| INN | levcromakalim |
| Description | Cromakalim (INN) is a potassium channel-opening vasodilator. The active isomer is levcromakalim. It acts on ATP-sensitive potassium channels and so causes membrane hyperpolarization. It can be used to treat hypertension as it will relax vascular smooth muscle to lower blood pressure. Hyperpolarisation of smooth muscle cell membranes pulls their membrane potential away from the threshold, so making it more difficult to excite them and thereby cause relaxation.
|
| Classification | Small molecule |
| Drug class | potassium channel agonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)Oc2ccc(C#N)cc2[C@@H](N2CCCC2=O)[C@@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 94535-50-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL100 |
| ChEBI ID | 6436 |
| PubChem CID | 71191 |
| DrugBank | — |
| UNII ID | RW7PN4BLDJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 509 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more